These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16623636)

  • 1. Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.
    García-Benayas T; Rendón AL; Rodríguez-Novóa S; Barrios A; Maida I; Blanco F; Barreiro P; Rivas P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Apr; 22(4):333-7. PubMed ID: 16623636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
    Barrios A; Rendón A; Negredo E; Barreiro P; Garcia-Benayas T; Labarga P; Santos J; Domingo P; Sánchez-Conde M; Maida I; Martín-Carbonero L; Núñez M; Blanco F; Clotet B; Sambeat MA; Gil P; Gonzalez-Lahoz J; Cooper D; Soriano V
    AIDS; 2005 Mar; 19(6):569-75. PubMed ID: 15802975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.
    Young B; Weidle PJ; Baker RK; Armon C; Wood KC; Moorman AC; Holmberg SD;
    AIDS Patient Care STDS; 2006 Apr; 20(4):238-44. PubMed ID: 16623622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
    Negredo E; Moltó J; Burger D; Viciana P; Ribera E; Paredes R; Juan M; Ruiz L; Puig J; Pruvost A; Grassi J; Masmitjà E; Clotet B
    AIDS; 2004 Feb; 18(3):459-63. PubMed ID: 15090798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir.
    Karrer U; Ledergerber B; Furrer H; Elzi L; Battegay M; Cavassini M; Gayet-Ageron A; Hirschel B; Schmid P; Russotti M; Weber R; Speck RF;
    AIDS; 2005 Nov; 19(17):1987-94. PubMed ID: 16260905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunological effectiveness of the nucleoside/nucleotide analog combinations, tenofovir + lamivudine, didanosine + lamivudine and tenofovir + didanosine, in patients with HIV infection and sustained viral suppression].
    Cervero M; Torres R; Jusdado JJ; Rodríguez-Rosado R; Del Alamo M; García-Benaya E
    Enferm Infecc Microbiol Clin; 2006; 24(7):426-30. PubMed ID: 16956530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal study on mitochondrial effects of didanosine-tenofovir combination.
    López S; Negredo E; Garrabou G; Puig J; Ruiz L; Sanjurjo E; Ramos X; Infante AB; Casademont J; Cardellach F; Clotet B; Miró O
    AIDS Res Hum Retroviruses; 2006 Jan; 22(1):33-9. PubMed ID: 16438643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
    Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
    Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
    Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
    Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland.
    Riordan A; Judd A; Boyd K; Cliff D; Doerholt K; Lyall H; Menson E; Butler K; Gibb D;
    Pediatr Infect Dis J; 2009 Mar; 28(3):204-9. PubMed ID: 19209091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
    Tung MY; Mandalia S; Bower M; Gazzard B; Nelson M
    HIV Med; 2005 May; 6(3):151-4. PubMed ID: 15876280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
    Barrios A; Negredo E; Domingo P; Estrada V; Labarga P; Asensi V; Morales D; Santos J; Clotet B; Soriano V;
    Antivir Ther; 2005; 10(7):825-32. PubMed ID: 16312178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically stable treatment-experienced adults receiving tenofovir and didanosine.
    Di Biagio A; Beltrame A; Cenderello G; Ferrea G; De Maria A
    HIV Clin Trials; 2006; 7(1):10-5. PubMed ID: 16632460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.
    Bongiovanni M; Tordato F
    Curr Med Chem; 2006; 13(23):2789-93. PubMed ID: 17073629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.
    Maitland D; Moyle G; Hand J; Mandalia S; Boffito M; Nelson M; Gazzard B
    AIDS; 2005 Jul; 19(11):1183-8. PubMed ID: 15990571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.
    Martínez E; Milinkovic A; de Lazzari E; Ravasi G; Blanco JL; Larrousse M; Mallolas J; García F; Miró JM; Gatell JM
    Lancet; 2004 Jul 3-9; 364(9428):65-7. PubMed ID: 15234858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
    Hawkins T; Veikley W; Durand-Gasselin L; Babusis D; Reddy YS; Flaherty JF; Ray AS
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1549-55. PubMed ID: 21282432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
    Nishijima T; Kawasaki Y; Tanaka N; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Gatanaga H; Oka S
    AIDS; 2014 Aug; 28(13):1903-10. PubMed ID: 25259702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.